Biogen Inc.

Healthcare · Drug Manufacturers - General

227.50$ +1.0% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Income Statement

Biogen Inc. (BIIB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 2,736 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement BIIB
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	2,956	2,872	2,811	3,078	3,078	3,307	3,131	3,357	3,439	3,526	3,490	3,617	3,600	3,671	3,534	3,682	3,376	2,853	2,694	2,775	2,779	2,734	2,532	2,589	2,509	2,544	2,463	2,456	2,530	2,386	2,291	2,465	2,466	2,455	2,431	2,646	2,455	2,279	2,478	2,736	9,948
Cost of Revenue	417	326	385	366	370	509	446	421	461	489	602	476	430	447	454	411	449	491	478	460	512	660	754	484	470	571	663	593	660	618	498	956	639	584	578	946	877	496	661	1,179	3,213
Gross Profit	2,539	2,546	2,426	2,712	2,708	2,798	2,685	2,936	2,978	3,038	2,888	3,140	3,170	3,224	3,080	3,271	2,927	2,362	2,216	2,315	2,267	2,074	1,778	2,105	2,039	1,973	1,800	1,863	1,871	1,768	1,792	1,509	1,827	1,871	1,853	1,699	1,578	1,783	1,817	1,557	6,735
Research & Development	529	534	423	916	446	588	507	1,056	535	612	564	485	540	692	623	709	1,224	1,975	612	1,207	813	768	619	596	606	777	621	637	797	648	524	592	673	684	546	530	370	509	573	496	1,947
Selling, General & Administrative	463	389	499	430	434	480	501	516	498	504	568	588	555	592	570	555	573	701	561	637	654	701	628	573	561	584	605	548	788	537	582	554	588	612	573	584	595	683	607	710	2,595
Total Operating Expenses	1,114	1,660	1,401	1,511	1,054	1,332	1,150	1,722	1,281	1,595	1,385	1,185	1,364	1,447	1,260	1,296	1,841	2,693	1,242	1,845	1,468	1,567	1,254	1,169	1,169	1,415	1,226	1,174	1,550	1,256	1,102	1,143	1,250	1,362	1,121	1,111	964	1,840	1,419	1,239	5,463
Operating Income	1,425	886	1,025	1,201	1,654	1,466	1,535	1,213	1,698	1,443	1,503	1,956	1,806	1,778	1,820	1,975	1,086	-331	974	471	800	507	524	936	870	558	574	690	321	512	690	367	577	509	733	588	614	-57	397	318	1,272
Interest Expense	66	65	63	64	62	62	51	52	49	49	48	48	46	46	44	66	56	56	65	56	66	66	66	66	60	55	63	49	64	72	69	61	60	60	60	73	67	68	68	82	285
Pre-Tax Income	1,367	838	987	1,132	1,610	1,400	1,494	1,179	1,813	1,415	1,831	1,742	1,757	1,716	1,685	2,053	945	371	449	616	292	423	344	1,275	1,371	604	438	708	-141	292	465	699	451	292	311	744	557	-211	378	132	856
Income Tax Expense	337	190	239	270	384	1,566	323	264	370	470	423	248	211	276	292	446	241	13	44	-409	-26	443	126	217	236	54	51	115	-73	43	71	115	63	25	71	109	91	-163	58	35	21
Net Income	1,033	649	748	863	1,226	-297	1,173	867	1,444	947	1,409	1,494	1,546	1,440	1,399	1,542	702	358	410	449	329	368	304	1,058	1,135	550	388	592	-68	250	393	584	389	267	241	635	467	-48	320	98	835
EBITDA	1,623	1,545	1,547	1,525	1,861	1,695	1,710	1,463	1,990	1,852	1,751	2,078	2,061	1,854	2,010	2,097	1,172	-187	1,087	621	955	713	785	1,042	945	765	630	751	396	601	780	968	714	692	865	1,110	827	212	554	78	1,671

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings